Shattuck Labs, Inc. Net Income
Shattuck Labs, Inc. (STTK) reported Net Income of -$15.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-11
- Shattuck Labs, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$15.15M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$14.77M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$12.59M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$10.06M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for fiscal 2023 was -$87.30M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for fiscal 2022 was -$101.94M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for fiscal 2021 was -$44.97M.
- Shattuck Labs, Inc. net income (loss) attributable to parent for fiscal 2020 was -$36.60M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$15.15M 10-Q · filed 2026-08-11 | -$29.92M 10-Q · filed 2026-08-11 | -$42.51M derived: sum of 3 quarters · filed 2026-08-11 | -$52.57M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$14.77M 10-Q · filed 2026-08-11 | -$27.36M derived: sum of 2 quarters · filed 2026-08-11 | -$37.42M derived: sum of 3 quarters · filed 2026-08-11 | -$49.87M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$12.59M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-08 | -$22.65M derived: sum of 2 quarters · filed 2026-04-08 | -$35.11M derived: sum of 3 quarters · filed 2026-08-11 | -$48.81M DEF 14A · filed 2026-04-08 | |
| 2025-09-30 | -$10.06M 10-Q · filed 2025-11-06 | -$22.51M derived: sum of 2 quarters · filed 2026-08-11 | -$36.22M 10-Q · filed 2025-11-06 | -$54.90M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$12.46M 10-Q · filed 2026-08-11 | -$26.16M 10-Q · filed 2026-08-11 | -$44.84M derived: sum of 3 quarters · filed 2026-08-11 | -$61.51M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$13.70M 10-Q · filed 2026-08-11 | -$32.38M derived: sum of 2 quarters · filed 2026-08-11 | -$49.06M derived: sum of 3 quarters · filed 2026-08-11 | -$70.61M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2024-12-31 | -$18.68M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-08 | -$35.35M derived: sum of 2 quarters · filed 2026-04-08 | -$56.91M derived: sum of 3 quarters · filed 2026-04-08 | -$75.41M DEF 14A · filed 2026-04-08 | |
| 2024-09-30 | -$16.68M 10-Q · filed 2025-11-06 | -$38.23M derived: sum of 2 quarters · filed 2025-11-06 | -$56.73M 10-Q · filed 2025-11-06 | -$74.42M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$21.55M 10-Q · filed 2025-11-06 | -$40.06M 10-Q · filed 2025-08-14 | -$57.74M derived: sum of 3 quarters · filed 2025-11-06 | -$85.28M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-03-31 | -$18.50M 10-Q · filed 2025-11-06 | -$36.19M derived: sum of 2 quarters · filed 2025-11-06 | -$63.73M derived: sum of 3 quarters · filed 2025-11-06 | -$85.08M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2023-12-31 | -$17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$45.23M derived: sum of 2 quarters · filed 2025-03-27 | -$66.57M derived: sum of 3 quarters · filed 2025-03-27 | -$87.30M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$27.54M 10-Q · filed 2024-11-14 | -$48.89M derived: sum of 2 quarters · filed 2024-11-14 | -$69.61M 10-Q · filed 2024-11-14 | -$95.02M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$21.35M 10-Q · filed 2024-11-14 | -$42.07M 10-Q · filed 2024-08-01 | -$67.48M derived: sum of 3 quarters · filed 2024-11-14 | -$92.12M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-03-31 | -$20.72M 10-Q · filed 2024-11-14 | -$46.13M derived: sum of 2 quarters · filed 2024-11-14 | -$70.77M derived: sum of 3 quarters · filed 2024-11-14 | -$98.14M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2022-12-31 | -$25.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$50.05M derived: sum of 2 quarters · filed 2024-02-29 | -$77.42M derived: sum of 3 quarters · filed 2024-02-29 | -$101.94M 10-K · filed 2024-02-29 | |
| 2022-09-30 | -$24.64M 10-Q · filed 2023-11-09 | -$52.01M derived: sum of 2 quarters · filed 2023-11-09 | -$76.53M 10-Q · filed 2023-11-09 | -$68.69M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$27.37M 10-Q · filed 2023-11-09 | -$51.90M 10-Q · filed 2023-08-10 | -$44.05M derived: sum of 3 quarters · filed 2023-11-09 | -$61.46M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-03-31 | -$24.53M 10-Q · filed 2023-11-09 | -$16.68M derived: sum of 2 quarters · filed 2023-11-09 | -$34.09M derived: sum of 3 quarters · filed 2023-11-09 | -$57.69M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2021-12-31 | $7.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$9.56M derived: sum of 2 quarters · filed 2023-02-23 | -$33.16M derived: sum of 3 quarters · filed 2023-02-23 | -$44.97M 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$17.41M 10-Q · filed 2022-11-09 | -$41.01M derived: sum of 2 quarters · filed 2022-11-09 | -$52.82M 10-Q · filed 2022-11-09 | -$64.83M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$23.60M 10-Q · filed 2022-11-09 | -$35.41M 10-Q · filed 2022-08-11 | -$47.42M derived: sum of 3 quarters · filed 2022-11-09 | -$59.25M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-03-31 | -$11.81M 10-Q · filed 2022-11-09 | -$23.82M derived: sum of 2 quarters · filed 2022-11-09 | -$35.65M derived: sum of 3 quarters · filed 2022-11-09 | -$41.86M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2020-12-31 | -$12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$23.84M derived: sum of 2 quarters · filed 2022-03-15 | -$30.05M derived: sum of 3 quarters · filed 2022-03-15 | -$36.60M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$11.83M 10-Q · filed 2021-11-09 | -$18.04M derived: sum of 2 quarters · filed 2021-11-09 | -$24.59M 10-Q · filed 2021-11-09 | -$31.96M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$6.21M 10-Q · filed 2021-11-09 | -$5.97M 10-Q · filed 2020-11-13 | -$12.76M 10-Q · filed 2021-08-12 | -$20.13M derived: sum of 3 quarters · filed 2021-11-09 | -$27.41M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-03-31 | -$6.55M 10-Q · filed 2021-11-09 | -$6.79M 10-Q · filed 2020-11-13 | -$13.92M derived: sum of 2 quarters · filed 2021-11-09 | -$21.20M derived: sum of 3 quarters · filed 2021-11-09 | -$27.09M derived: sum of 4 quarters · filed 2021-11-09 |
| 2019-12-31 | -$7.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$14.65M derived: sum of 2 quarters · filed 2021-03-16 | -$20.53M derived: sum of 3 quarters · filed 2021-03-16 | -$23.98M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$7.28M 10-Q · filed 2020-11-13 | -$13.16M derived: sum of 2 quarters · filed 2020-11-13 | -$16.61M 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | -$5.88M 10-Q · filed 2020-11-13 | -$9.33M derived: sum of 2 quarters · filed 2020-11-13 | |||
| 2019-03-31 | -$3.45M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |